First human trial launches for experimental cancer pill targeting tough tumors
NCT ID NCT07345637
Summary
This is an early-stage study to test the safety and find the right dose of a new oral medication called FXS887 for adults with advanced solid tumors that have stopped responding to standard treatments. The trial will first test increasing doses in a small group of about 14 participants to see how their bodies handle the drug. If safe doses are found, the study may expand to gather more information on how the drug works and if it shows any signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR REFRACTORY TO CONVENTIONAL TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.